Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imunoglukan P4H
- Development stage
- Preclinical
- Lead developer
- Pleuran
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Imunoglukan P4H is a branded nutritional supplement designed to support the immune system. It is a combination product containing a patented, highly purified natural beta-(1,3/1,6)-D-glucan called pleuran (or IMG), which is isolated from the oyster mushroom *Pleurotus ostreatus*, and vitamin C (ascorbic acid). Some formulations may also include zinc. The product acts as a non-specific immunomodulator, promoting both innate and adaptive immunity. Clinical studies have investigated its effects on reducing the incidence of secondary infections in patients with Crohn's disease, as well as its potential to decrease the frequency of respiratory tract infections in children and athletes. It is available in various forms, including capsules and a liquid syrup. The product line is developed and manufactured by the Slovakian biotechnology company, Pleuran, s.r.o.
- Brand names
- Imunoglukan P4HDefendyl Imunoglukan P4H
- Other names
- Imunoglukan P4H
02
Targets
CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Imunoglukan P4H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imunoglukan P4H.